User profiles for S. J. Wort
 | Stephen John WortVerified email at rbht.nhs.uk Cited by 14600 |
[HTML][HTML] Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review
Introduction Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting
right ventricular (RV) failure occur in many critical illnesses and may be associated with a …
right ventricular (RV) failure occur in many critical illnesses and may be associated with a …
Inflammation in pulmonary arterial hypertension
LC Price, SJ Wort, F Perros, P Dorfmüller, A Huertas… - Chest, 2012 - Elsevier
… Financial/nonfinancial disclosures: The authors have reported to CHEST the following
conflicts of interest: Dr Wort has relationships with Actelion, Bayer Schering, GSK, Novartis, and …
conflicts of interest: Dr Wort has relationships with Actelion, Bayer Schering, GSK, Novartis, and …
The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension
D Shao, JES Park, SJ Wort - Pharmacological Research, 2011 - Elsevier
The term pulmonary arterial hypertension (PAH) describes a rare group of diseases
characterized by raised pulmonary vascular resistance, resulting from vascular remodelling in the …
characterized by raised pulmonary vascular resistance, resulting from vascular remodelling in the …
Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United …
…, JL Lordan, S Gaine, JG Coghlan, SJ Wort… - American journal of …, 2012 - atsjournals.org
Rationale: Incident pulmonary arterial hypertension was underrepresented in most pulmonary
hypertension registries and may have a different disease profile to prevalent disease. …
hypertension registries and may have a different disease profile to prevalent disease. …
Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre
Background— Adult congenital heart disease (ACHD) patients have ongoing morbidity and
reduced long-term survival. Recently, the importance of specialized follow-up at tertiary …
reduced long-term survival. Recently, the importance of specialized follow-up at tertiary …
Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations
…, S Trenfield, R Trimlett, C Weaver, SJ Wort… - American journal of …, 2020 - atsjournals.org
Rationale: Clinical and epidemiologic data in coronavirus disease (COVID-19) have accrued
rapidly since the outbreak, but few address the underlying pathophysiology. Objectives: To …
rapidly since the outbreak, but few address the underlying pathophysiology. Objectives: To …
Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension
…, S Goletto, G Giannakoulas, L Swan, SJ Wort… - Circulation, 2010 - Am Heart Assoc
Background— Advanced therapy (AT) for pulmonary arterial hypertension in the context of
congenital heart disease (Eisenmenger syndrome) improves pulmonary hemodynamics, …
congenital heart disease (Eisenmenger syndrome) improves pulmonary hemodynamics, …
Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom National Cohort
…, B Schreiber, G Coghlan, K Dimopoulos, SJ Wort… - Circulation, 2016 - Am Heart Assoc
… Dr Wort has received speaker fees and honoraria from Actelion and Pfizer, has received
research grants from Actelion, Pfizer, and Bayer, and is on advisory boards for Pfizer, GSK, …
research grants from Actelion, Pfizer, and Bayer, and is on advisory boards for Pfizer, GSK, …
Thrombosis and COVID-19 pneumonia: the clot thickens!
…, C McCabe, B Garfield, SJ Wort - European Respiratory …, 2020 - Eur Respiratory Soc
… Wort … Conflict of interest: SJ Wort reports grants and personal fees from Actelion
Pharmaceuticals and Bayer, personal fees from MSD and GSK, outside the submitted work. …
Pharmaceuticals and Bayer, personal fees from MSD and GSK, outside the submitted work. …
[HTML][HTML] Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the …
variation within components of the transforming growth factor-β pathway, particularly the …